Amgen v. Apotex: Amgen’s Reply Brief Filed in Fed. Cir. Appeal

Amgen v. Apotex (pegfilgrastim)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  U.S. Biosimilar Litigation News

Amgen has filed its reply brief in Amgen v. Apotex, which is currently on appeal before the Federal Circuit.  The brief is available here.

As we covered previously, Apotex filed an appeal in the Federal Circuit after the district court granted Amgen a preliminary injunction to prevent Apotex from marketing its biosimilar pegfilgrastim product until 180 days after Apotex provides a post-FDA-licensure notice that it intends to begin commercial marketing of the biosimilar.

Apotex filed its opening brief on December 30, 2015.

Stay tuned for further coverage.

 

 

Download PDF

Comments are closed.